New York, NY (PRWEB) March 07, 2013
The nation’s first trial of a Fosamax lawsuit that claims the popular osteoporosis drug increases the risk for certain types of femur fractures will begin next week in New Jersey’s Atlantic County Superior Court, Bernstein Liebhard LLP reports. According to court records, jury selection in the Fosamax femur fracture case is set to start on March 11th. The New Jersey Fosamax lawsuit was filed on behalf of a woman who took Fosamax for more than five years before suffering femur fractures in both legs. She claims Merck Sharp & Dohme Corp. failed to warn patients and doctors about the risks associated with the bone loss drug. (Su v. Merck Sharp & Dohme Corp., case number ATL-L-0789-11)
“We are looking forward to the start of this trial. Although there have been a number of trials concerning Fosamax and its relation to other injuries, this is the first time a jury will hear claims concerning Fosamax femur fractures,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, including dozens of women suffering injuries as a result of their long-term use of Fosamax. The Firm is currently offering free legal evaluations to alleged victims of Fosamax femur fractures.
Fosamax Femur Fracture Lawsuits
Court records indicate that 2,566 Fosamax lawsuits have been filed in a consolidated litigation underway in Atlantic County. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct) The claims allege plaintiffs suffered femur fractures and other serious side effects due to their use of Fosamax. In addition to the litigation underway in New Jersey Superior Court, additional Fosamax lawsuits involving femur facture allegations have been consolidated in a multidistrict litigation in U.S. District Court, District of New Jersey (In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II) - MDL No. 2243). Court documents indicate that the first of more than 800 Fosamax lawsuits pending in the federal litigation will also go to trial this year.
Fosamax has been used by millions of post-menopausal women to prevent fractures from osteoporosis. In October 2010, the U.S. Food & Drug Administration (FDA) added new information to the Fosamax label after studies indicated that people taking bisphosphonates for osteoporosis are at risk of suffering atypical femur fractures. Among other things, the FDA advised doctors to consider periodic reevaluation of bisphosphonate therapy, particularly in patients who have been treated for over 5 years.*
In May 2012, an FDA-commissioned analysis published in the New England Journal of Medicine raised additional concerns about the long-term risks associated with drugs like Fosamax. The study concluded that there was little benefit in taking bisphosphonates for longer than five years due to their association with serious side effects, including atypical femur fractures.**
Victims of femur fractures that might be associated with the use of Fosamax may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. A wealth of information regarding Fosamax lawsuits is available by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. To arrange for a free case review, please contact Bernstein Liebhard LLP at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP